# Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

> **NCT00448916** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 54 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT00448916
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448916, "Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00448916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*